Manjulata Singh1, Gayatri Padhy1, Praveen Vats1, Kalpana Bhargava2, Niroj Kumar Sethy3. 1. Defence Institute of Physiology and Allied Sciences, Defence Research and Development Organisation, Lucknow Road, Timarpur, Delhi 110054, India. 2. Defence Institute of Physiology and Allied Sciences, Defence Research and Development Organisation, Lucknow Road, Timarpur, Delhi 110054, India. Electronic address: kalpanab2006@gmail.com. 3. Defence Institute of Physiology and Allied Sciences, Defence Research and Development Organisation, Lucknow Road, Timarpur, Delhi 110054, India. Electronic address: nksethy@gmail.com.
Abstract
BACKGROUND: This study was aimed to evaluate regulation of cardiac arginase expression during hypobaric hypoxia and subsequent effect on nitric oxide availability and signaling. METHODS: Rats were exposed to hypobaric hypoxia (282mmHg for 3h) and ARG1 expression was monitored. The expression levels of eNOS and eNOS(Ser1177) were determined by Western blotting, cGMP levels were measured by ELISA and amino acid concentrations were measured by HPLC analysis. Transcription regulation of arginase was monitored by chromatin immunoprecipitation (ChIP) assay with anti-c-Jun antibody for AP-1 consensus binding site on ARG1 promoter. Arginase activity was inhibited by intra-venous dose of N-(ω)-hydroxy-nor-l-arginine (nor-NOHA) prior to hypoxia exposure and subsequent effect on NO availability and oxidative stress were evaluated. RESULTS: Hypobaric hypoxia induced cardiac arginase expression by recruiting c-Jun to AP-1 binding site on ARG1 promoter. This increased expression redirected l-arginine towards arginase and resulted in limited endothelial nitric oxide synthase (eNOS) activity, nitric oxide (NO) availability and cGMP mediated signaling. Inhibition of arginase restored the eNOS activity, promoted cardiac NO availability and ameliorated peroxynitrite formation during hypoxia. CONCLUSIONS: Hypoxic induced arginase under transcription control of AP-1 reciprocally regulates eNOS activity and NO availability in the heart. This also results in cardiac oxidative stress. GENERAL SIGNIFICANCE: This study provides understanding of hypoxia-mediated transcriptional regulation of arginase expression in the heart and its subsequent effect on eNOS activity, NO availability and signaling as well as cardiac oxidative stress. This information will support the use of arginase inhibitors as therapeutics for pathological hypoxia.
BACKGROUND: This study was aimed to evaluate regulation of cardiac arginase expression during hypobaric hypoxia and subsequent effect on nitric oxide availability and signaling. METHODS:Rats were exposed to hypobaric hypoxia (282mmHg for 3h) and ARG1 expression was monitored. The expression levels of eNOS and eNOS(Ser1177) were determined by Western blotting, cGMP levels were measured by ELISA and amino acid concentrations were measured by HPLC analysis. Transcription regulation of arginase was monitored by chromatin immunoprecipitation (ChIP) assay with anti-c-Jun antibody for AP-1 consensus binding site on ARG1 promoter. Arginase activity was inhibited by intra-venous dose of N-(ω)-hydroxy-nor-l-arginine (nor-NOHA) prior to hypoxia exposure and subsequent effect on NO availability and oxidative stress were evaluated. RESULTS:Hypobaric hypoxia induced cardiac arginase expression by recruiting c-Jun to AP-1 binding site on ARG1 promoter. This increased expression redirected l-arginine towards arginase and resulted in limited endothelial nitric oxide synthase (eNOS) activity, nitric oxide (NO) availability and cGMP mediated signaling. Inhibition of arginase restored the eNOS activity, promoted cardiac NO availability and ameliorated peroxynitrite formation during hypoxia. CONCLUSIONS: Hypoxic induced arginase under transcription control of AP-1 reciprocally regulates eNOS activity and NO availability in the heart. This also results in cardiac oxidative stress. GENERAL SIGNIFICANCE: This study provides understanding of hypoxia-mediated transcriptional regulation of arginase expression in the heart and its subsequent effect on eNOS activity, NO availability and signaling as well as cardiac oxidative stress. This information will support the use of arginase inhibitors as therapeutics for pathological hypoxia.
Authors: Min Zhu; Sean C Goetsch; Zhaoning Wang; Robert Luo; Joseph A Hill; Jay Schneider; Sidney M Morris; Zhi-Ping Liu Journal: Circ Res Date: 2015-10-05 Impact factor: 17.367
Authors: Lin Wang; Anil Bhatta; Haroldo A Toque; Modesto Rojas; Lin Yao; Zhimin Xu; Chintan Patel; Ruth B Caldwell; R William Caldwell Journal: Microvasc Res Date: 2014-11-07 Impact factor: 3.514
Authors: Bernardo J Krause; Paola Casanello; Ana C Dias; Paulina Arias; Victoria Velarde; German A Arenas; Marcelo D Preite; Rodrigo Iturriaga Journal: Front Physiol Date: 2018-07-24 Impact factor: 4.566
Authors: Pablo Rayff da Silva; Renan Fernandes do Espírito Santo; Camila de Oliveira Melo; Fábio Emanuel Pachú Cavalcante; Thássia Borges Costa; Yasmim Vilarim Barbosa; Yvnni M S de Medeiros E Silva; Natália Ferreira de Sousa; Cristiane Flora Villarreal; Ricardo Olímpio de Moura; Vanda Lucia Dos Santos Journal: Pharmaceutics Date: 2022-01-13 Impact factor: 6.321